Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib Monotherapy and in Combination With Pembrolizumab in Advanced NSCLC With KRAS G12C Mutation
NCT04613596Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Dec 2020
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 47
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Dec 2020; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04613596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613596.